Vizamyl Expanded Indications for Positron Emission Tomography Imaging and Quantification Overview

 

Join us for this live education event that will explore the recent FDA label expansion for Vizamyl and how it can impact clinical practice in Alzheimer’s disease diagnostics and treatment planning.

 

Webinar highlights:

  • Learn about the recent label expansion recognizing amyloid PET quantification as an adjunct to visual interpretation
  • Gain practical education on how amyloid PET quantification works, including the use of the Centiloid scale to standardize results
  • Understand how Vizamyl can support patient selection for anti-amyloid therapies
  • Align practice with updated Appropriate Use Criteria (AUC) for amyloid PET, Alzheimer’s Association (AA) criteria for Alzheimer’s disease diagnosis and staging, and International Working Group (IWG) framework

Meet the Speaker:

 
 
 

Dr. Alexis Moscoso, Ph.D.
Chief Scientific Officer at ZRO Imaging

  • Ph.D. in Clinical Research in Medicine
  • Extensive academic and industry experience in PET imaging and fluid biomarkers in Alzheimer’s disease and other neurodegenerative disorders
  • Author of 50+ peer-reviewed publications on tau PET, amyloid PET, and fluid biomarkers in neurodegenerative diseases, including high-impact articles in journals such as JAMA, JAMA Neurology, Alzheimer’s & Dementia, and Brain
  • Principal investigator in observational studies using PET imaging in Alzheimer’s disease, with active contributions to multiple international clinical trial collaborations
  • Frequent speaker at AAIC, AD/PD, CTAD, and other global conferences

This event is intended for HealthCare Professionals only.
The event is sponsored by GE HealthCare.
The speaker will provide guidance based on their own practices and knowledge.
GE HealthCare and the speakers accept no responsibility for the use of guidance provided at this event.

 

Register Now

 
 
 

Vizamyl Important Safety Information

 

Product Indications and Use

VIZAMYL™ (flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:

  • Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline
  • Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products.

Contraindications

VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80.

 

Adverse Reactions

The most commonly reported adverse reactions in clinical trials were flushing (2 %), increased blood pressure (2 %), headache (1 %), nausea and dizziness (1 %). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

 

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800 654 0118 (option 2 then option 1) or by email at [email protected] or FDA at 800 FDA 1088 or www.fda.gov/medwatch.  

 

Access full updated Prescribing Information at https://gehealthcare.com/vizamyl-pi.

 

GE HealthCare | Privacy Policy | Terms of Use | Contact Us | Unsubscribe

500 W. Monroe Street | Chicago, IL 60661

 

© 2025 GE HealthCare
Vizamyl is a trademark of GE HealthCare.
GE is a trademark of General Electric Company used under trademark license.
September 2025 JB12408US